May 31, 2024 10:58 AM EDT
News Briefing

No­var­tis shares up­dat­ed da­ta for BTK in­hibitor; Astel­las re­sub­mits BLA for can­cer drug af­ter CRL

ENDPOINTS

Plus, news about Valar Labs, Pharm­ing Group and Day One Phar­ma­ceu­ti­cals:

No­var­tis out­lines one-year da­ta for BTK in­hibitor: The drug, called remi­bru­ti­nib,

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times